Blistering Disorders

Autoimmune (antibody-mediated) causes

• Loss of tolerance to adhesion proteins: anti-desmoglein IgG (pemphigus), anti-BP180/BP230 IgG (bullous pemphigoid), and anti-epidermal transglutaminase IgA (dermatitis herpetiformis) — the target antigen determines the plane of cleavage and therefore the clinical blister.
• Paraneoplastic pemphigus: antibodies against plakins/desmogleins driven by an underlying lymphoproliferative neoplasm — Castleman disease, non-Hodgkin lymphoma, CLL, thymoma.

Drug-induced causes (the most commonly planted stem clue)

• Thiol/sulfhydryl drugs: penicillamine, captopril → pemphigus foliaceus-like disease.
• Vancomycin: classic trigger of linear IgA bullous dermatosis ("string of pearls" annular bullae).
• DPP-4 inhibitors (gliptins) and PD-1/PD-L1 checkpoint inhibitors: increasingly recognized precipitants of bullous pemphigoid; loop diuretics are also implicated.
• SJS/TEN triggers: aromatic anticonvulsants (carbamazepine, lamotrigine, phenytoin), allopurinol, sulfonamides, nevirapine, NSAIDs — a delayed T-cell (granulysin/Fas-FasL) keratinocyte apoptosis, typically 1–4 weeks after drug start.

Genetic and infectious/toxin-mediated causes

• Structural gene mutations: keratin and collagen XVII/laminin defects underlie epidermolysis bullosa (already detailed above).
• Staphylococcal exfoliative toxin: cleaves desmoglein 1 → staphylococcal scalded skin syndrome, a mimic rather than an autoimmune disease.

Non-modifiable risk factors

• Advanced age: bullous pemphigoid is a disease of the elderly; neurologic disease (dementia, stroke, Parkinson) is a well-described association.
• HLA associations: DRB1*04:02 and DQB1*03:02 with pemphigus vulgaris (Ashkenazi Jewish and Mediterranean ancestry); HLA-DQ2/DQ8 with dermatitis herpetiformis. FDA labeling recommends HLA-B*15:02 testing before carbamazepine in patients of Southeast Asian ancestry, and the ACR gout guideline recommends HLA-B*58:01 testing before allopurinol in Southeast Asian and Black African ancestry patients.

Modifiable risk factors

• Culprit drug exposure, dietary gluten and iodine (both flare dermatitis herpetiformis), trauma/friction and burns, UV exposure, and chronic immunosuppression predisposing to infectious mimics.

Autoimmune Blistering Disorders (Acantholytic vs. Subepidermal)

• Pemphigus (acantholytic): IgG autoantibodies against desmoglein (desmosomal cell adhesion molecules) cause loss of cell-cell adhesion (acantholysis) within the epidermis, creating intraepidermal blistering
• Pemphigus vulgaris: antibodies against desmoglein 3 (and sometimes 1); affects mucous membranes and skin
• Pemphigus foliaceus: antibodies against desmoglein 1 only; superficial blistering, spares mucous membranes

• Bullous pemphigoid: IgG autoantibodies against BP180 and BP230 (hemidesmosmal antigens at the basement membrane zone) cause complement-mediated destruction of the dermal-epidermal junction, resulting in subepidermal blistering with intact epidermis above

• Linear IgA disease: Linear deposits of IgA along the basement membrane zone; can mimic bullous pemphigoid clinically but distinct serologically

Genetic Blistering Disorders

• Epidermolysis bullosa simplex: mutations in KRT5 or KRT14 (keratin genes) disrupt intracellular keratin networks, causing intraepidermal acantholysis with minimal trauma
• Bullous pemphigoid-like genetic forms: mutations in COL17A1 (collagen XVII) or LAMA3 affecting basement membrane adherence

Pemphigus Vulgaris (Most Severe Variant)

• Flaccid blisters that rupture easily, leaving painful erosions and crusting
• Mucous membrane involvement is pathognomonic and often precedes skin manifestations (oral erosions, difficulty eating/drinking)
• Positive Nikolsky sign (gentle lateral pressure causes epidermal sloughing) — indicates acantholysis
• Often affects face, scalp, flexural surfaces, and intertriginous areas
• Painful oral erosions may be the only initial presentation in up to 50% of cases

Pemphigus Foliaceus

• Superficial blistering with more fragile, flaccid blisters that rupture into crusts
• Spares mucous membranes (key distinguishing feature from pemphigus vulgaris)
• Presents with crusty plaques, scaling, and erosions
• More localized variants include drug-induced pemphigus (penicillamine, captopril) and paraneoplastic pemphigus

Bullous Pemphigoid

• Tense bullae (don't rupture easily) on erythematous or normal base, often on flexural surfaces
• Blisters form from subepidermal separation, so the roof is thicker and more intact
• Negative Nikolsky sign (distinguishes from pemphigus) — epidermis remains intact above bulla
• Often preceded by urticarial or eczematous lesions
• Commonly affects elderly patients (peak incidence 60+ years)
• Oral involvement is less common than in pemphigus vulgaris

Dermatitis Herpetiformis (DH)

• Intensely pruritic vesicles and papules in grouped/herpetiform distribution (face, extensor surfaces, buttocks, scalp)
• Patients report severe burning and pruritus before clinical lesions appear
• Associated with celiac disease (gluten-sensitive enteropathy) in nearly 100% of cases, though GI symptoms may be absent

Epidermolysis Bullosa Simplex

• Blisters form at sites of minor trauma with intraepidermal acantholysis
• Range from localized (hands/feet) to generalized; typically non-scarring
• Onset often in infancy/early childhood

Immunofluorescence (Gold Standard for Autoimmune Blistering)

• Direct immunofluorescence (DIF): Demonstrates in vivo antibody/complement deposition in patient skin
• Pemphigus: Intercellular IgG (honeycomb pattern) throughout epidermis
• Bullous pemphigoid: Linear IgG and C3 at basement membrane zone
• Dermatitis herpetiformis: Granular IgA at dermal-epidermal junction

• Indirect immunofluorescence (IIF): Detects circulating autoantibodies in serum (more specific, less sensitive than DIF)

Serology

• ELISA/immunoblot: Identifies specific antigens (desmoglein 1 vs. 3 in pemphigus; BP180/BP230 in bullous pemphigoid)
• Desmoglein 3-positive antibodies with negative desmoglein 1 = mucosal-dominant pemphigus vulgaris
• Desmoglein 3-positive AND desmoglein 1-positive = mucocutaneous pemphigus vulgaris

Histopathology (Skin Biopsy)

• Pemphigus: Acantholysis with tombstone acantholytic cells (rounded keratinocytes floating in blister cavity) within the epidermis
• Bullous pemphigoid: Subepidermal blister with intact epidermis above; eosinophil-rich infiltrate; preserved dermal-epidermal junction integrity
• Dermatitis herpetiformis: Subepidermal blister with neutrophilic microabscesses at dermal papillae

Additional Diagnostic Considerations

• Biopsy should include perilesional tissue (edge of blister) for optimal immunofluorescence results
• Serologic titers may correlate with disease activity in some pemphigus variants
• Skin biopsy from a fresh blister is superior to biopsy from an erosion (better preservation of diagnostic features)

Pemphigus Vulgaris (Most Severe — Requires Aggressive Therapy)

• Systemic corticosteroids: Prednisone 0.5-1 mg/kg/day (often 40-60 mg/day initially), taper slowly over months based on response
• Goal: achieve control of new blister formation and begin gradual taper
• Disease activity may flare with rapid taper; monitor Nikolsky sign and blister count

• Topical corticosteroids: High-potency agents (clobetasol 0.05%) for localized lesions and erosions

• Azathioprine (1-2 mg/kg/day) or mycophenolate mofetil (1-3 g/day in divided doses) — allows reduction of systemic steroid doses
• Rituximab (anti-CD20 monoclonal antibody): increasingly used as steroid-sparing agent; induces remission in refractory cases
• Intravenous immunoglobulin (IVIG): 2 g/kg monthly in refractory disease or as bridge therapy

• Dapsone (100-200 mg/day): may provide steroid-sparing benefit in some cases; requires baseline G6PD screening
• PPI and bone-protective agents (calcium, vitamin D, bisphosphonates) due to prolonged systemic steroid

Complications of the disease

• Secondary bacterial infection and sepsis (EMERGENCY): denuded epidermis loses barrier function → Staphylococcus aureus, Streptococcus pyogenes, and Pseudomonas invasion. Signaled by fever, purulent or malodorous erosions, hypotension, or expanding erythema; blood and wound cultures plus empiric antibiotics per IDSA skin and soft-tissue infection guidance.
• Fluid, electrolyte, and protein loss (EMERGENCY in extensive disease): transepidermal water loss mimics a burn; tachycardia, oliguria, hypernatremia, and hypoalbuminemia signal it. Extensive TEN warrants immediate culprit-drug withdrawal and burn-unit transfer; SCORTEN is the validated bedside severity score.
• Ocular scarring (EMERGENCY for vision): conjunctival inflammation in SJS/TEN and mucous membrane pemphigoid → symblepharon, entropion, corneal scarring, blindness. Any eye redness or photophobia mandates same-day ophthalmology consultation.
• Mucosal stricture and malnutrition: esophageal, laryngeal, urethral, or vaginal erosions heal with stenosis; odynophagia, hoarseness, or weight loss are the tip-offs.
• Enteropathy-associated complications of dermatitis herpetiformis: untreated gluten exposure causes malabsorption (iron/folate deficiency, osteoporosis) and confers increased risk of small-bowel lymphoma — a lifelong gluten-free diet, as endorsed by the ACG celiac disease guideline, is the only disease-modifying therapy.

Complications of treatment

• Systemic glucocorticoids: hyperglycemia, hypertension, cataracts, avascular necrosis, adrenal suppression with abrupt taper, and glucocorticoid-induced osteoporosis — the ACR glucocorticoid-induced osteoporosis guideline directs calcium/vitamin D and risk-stratified bisphosphonate therapy. Prolonged high-dose therapy also warrants consideration of Pneumocystis prophylaxis.
• Azathioprine: myelosuppression, profound in TPMT or NUDT15 deficiency — check enzyme/genotype before starting; also long-term lymphoma and non-melanoma skin cancer risk.
• Mycophenolate: cytopenias, GI intolerance, and teratogenicity (REMS program, contraception required).
• Rituximab: hepatitis B reactivation (screen HBsAg and anti-HBc per AASLD), hypogammaglobulinemia, infusion reactions, and rare progressive multifocal leukoencephalopathy — new confusion or focal deficits demand urgent MRI.
• Dapsone: dose-dependent hemolysis (worse with G6PD deficiency), agranulocytosis, and methemoglobinemia — cyanosis with a saturation gap unresponsive to oxygen is an emergency treated with methylene blue.
• IVIG: thrombosis, aseptic meningitis, and acute kidney injury.

• Flaccid + mucosa + positive Nikolsky = pemphigus; tense + no mucosa + negative Nikolsky = bullous pemphigoid: the single most tested discriminator. Pemphigus is intraepidermal (blisters cannot stay intact); pemphigoid is subepidermal (thick roof).
• **Best next step in any suspected autoimmune blistering disease is a biopsy of perilesional skin for direct immunofluorescence**, paired with a lesional biopsy for routine histology. Choosing serology alone, or biopsying the center of a denuded erosion, is the classic wrong answer.
• Intensely pruritic grouped vesicles on extensors + granular IgA at dermal papillae = dermatitis herpetiformis: the association examiners want is celiac disease. Gluten-free diet is definitive therapy (ACG celiac guideline); dapsone gives rapid itch relief but does nothing for the enteropathy — check G6PD first.
• Drug buzzwords: vancomycin → linear IgA bullous dermatosis ("string of pearls"); penicillamine/captopril → pemphigus; DPP-4 inhibitors and checkpoint inhibitors → bullous pemphigoid; allopurinol, sulfonamides, and aromatic anticonvulsants → SJS/TEN.
• Intractable stomatitis that will not heal, plus lichenoid skin lesions and dyspnea, points to paraneoplastic pemphigus — search for Castleman disease, non-Hodgkin lymphoma, or CLL; bronchiolitis obliterans drives mortality.
• SSSS versus TEN is the perennial distractor: SSSS occurs in young children, spares mucous membranes, and splits the granular layer (exfoliative toxin cleaves desmoglein 1); TEN involves at least two mucosal sites with full-thickness epidermal necrosis and a positive Nikolsky sign. By the Bastuji-Garin consensus, SJS involves less than 10% body surface area, TEN more than 30%.
• First move in SJS/TEN is stopping the culprit drug and transferring to a burn or ICU setting with supportive care; systemic steroids are not the answer of choice, and IVIG has not shown consistent mortality benefit.
• Localized bullous pemphigoid responds to high-potency topical clobetasol — reaching for high-dose systemic prednisone in a frail elderly patient with limited disease is the trap. FDA-approved rituximab is now a preferred agent for moderate-to-severe pemphigus vulgaris rather than a last resort.